2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
8
Ovarian Neoplasms
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Interventions
Fluorouracil
498
Bevacizumab
476
Oxaliplatin
450
Leucovorin
442
Irinotecan
408
Cetuximab
318
Capecitabine
317
pembrolizumab
142
Folfox protocol
128
Panitumumab
117
regorafenib
105
Colonoscopy
88
Nivolumab
82
IFL protocol
81
Drug Therapy
77
trifluridine tipiracil drug combination
73
Radiotherapy
66
HMPL-013
65
Blood Specimen Collection
52
Gemcitabine
49
Specimen Handling
47
Standard of Care
45
Neoadjuvant Therapy
45
Magnetic Resonance Spectroscopy
44
Biopsy
44
Chemotherapy, Adjuvant
41
Trifluridine
40
atezolizumab
39
Cyclophosphamide
39
Surveys and Questionnaires
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
tisotumab vedotin
×
Clear all
NCT03485209
2026-04-20
innovaTV 207
Seagen Inc.
Phase 2
Active not recruiting
350 enrolled